Exelixis
EXEL
#1694
Rank
ยฃ8.95 B
Marketcap
ยฃ33.27
Share price
-0.02%
Change (1 day)
17.80%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2025 : ยฃ2.11 Billion

According to Exelixis's latest financial reports the company's total assets are ยฃ2.11 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2025)

Total assets by year

Year Total assets Change
2024-12-31ยฃ2.34 B1.71%
2023-12-31ยฃ2.30 B-9.03%
2022-12-31ยฃ2.53 B30.99%
2021-12-31ยฃ1.93 B23.61%
2020-12-31ยฃ1.56 B9.04%
2019-12-31ยฃ1.43 B28.34%
2018-12-31ยฃ1.12 B131.09%
2017-12-31ยฃ0.48 B0.43%
2016-12-31ยฃ0.48 B115.29%
2015-12-31ยฃ0.22 B8.01%
2014-12-31ยฃ0.20 B-31.95%
2013-12-31ยฃ0.30 B-31.61%
2012-12-31ยฃ0.44 B76.33%
2011-12-31ยฃ0.25 B8.26%
2010-12-31ยฃ0.23 B10.13%
2009-12-31ยฃ0.21 B-22.56%
2008-12-31ยฃ0.27 B32.1%
2007-12-31ยฃ0.20 B2.76%
2006-12-31ยฃ0.20 B4.63%
2005-12-31ยฃ0.19 B27.14%
2004-12-31ยฃ0.15 B-24.13%
2003-12-31ยฃ0.20 B-5.43%
2002-12-31ยฃ0.21 B-11.53%
2001-12-31ยฃ0.23 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
GlaxoSmithKline
GSK
ยฃ61.85 B 2,820.45%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
ยฃ114.25 B 5,294.77%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ97.16 B 4,488.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ72.67 B 3,331.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ67.61 B 3,092.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
ยฃ144.62 B 6,728.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ156.56 B 7,292.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
ยฃ20.73 M-99.02%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
ยฃ75.93 M-96.41%๐Ÿ‡บ๐Ÿ‡ธ USA